Prosecution Insights
Last updated: November 04, 2026
Application No. 18/656,994

DIAGNOSTIC CARTRIDGE AND SEMICONDUCTOR BIOSENSOR DIAGNOSTIC SYSTEM COMPRISING THEREOF

Non-Final OA §102§103§112
Filed
May 07, 2024
Examiner
BORTOLI, JONATHAN
Art Unit
1797
Tech Center
1700 — Chemical & Materials Engineering
Assignee
BIOUP LABS TAIWAN CO., LTD.
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
195 granted / 255 resolved
+11.5% vs TC avg
Strong +40% interview lift
Without
With
+40.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
26 currently pending
Career history
275
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
41.2%
+1.2% vs TC avg
§102
23.7%
-16.3% vs TC avg
§112
29.0%
-11.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 255 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of AIA Status The present application, filed on 5/7/24, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-20 are pending. Claims 1-7 and 18-20 are withdrawn. Claims 8-17 are rejected. Election/Restrictions Applicant’s election without traverse of invention II, claims 8-17, in the reply filed on 10/06/26 is acknowledged. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 8-17 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claim 8 recites “the first pumping opening”. There is insufficient antecedent basis for this limitation in the claim. Claim 8 recites “the second pumping opening”. There is insufficient antecedent basis for this limitation in the claim. Claims 9-17 are also rejected under 35 U.S.C. 112(b) because any claim in dependent form is construed to incorporate by reference all the limitations of the claim to which it refers. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 8 and 14-15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hsiao (US20240036037, cited in the 9/21/26 IDS). With respect to claim 8, Hsiao teaches a diagnostic cartridge (fluidic cartridge module 120 in [0041], illustrated in Fig. 4), comprising: a case body (the lower casing 122 in [0042], illustrated as 124 in Fig. 4) having a recess (see Fig. 4); a biosensor device (biosensor package 123 in [0042]) embedded in the recess of the case body (lower casing 122) (see Fig. 4, element 124) (see [0042], which recites “the biosensor package 123 disposed in the casing 121, 122”); a fluid-guide body (first channel frame 126 in [0054] and second channel frame 125 in [0054]) in the case body (see Fig. 4, element 124), the fluid-guide body (first channel frame 126 and second channel frame 125) comprises: a sample reservoir (discharged chamber 1253 in [0065]) and a buffer reservoir (discharged chamber 1254 in [0065]) laterally between the first pumping opening (cartridge side opening in communication with “the second pump 160” in [0062]) and the second pumping opening (cartridge side opening in communication with “the first pump 150” in [0062], which recites “the first pump 150 and the second pump 160 are in fluid communication with the discharged chambers 1253, 1254 respectively”) from a side view perspective (see Fig. 12); and a plurality of channels (branches of “the fluidic channel 127” in [0054]), wherein one of the plurality of channels connects the sample reservoir (discharged chamber 1253) and the buffer reservoir (discharged chamber 1254) and crossing over the biosensor device (biosensor package 123), and the sample reservoir (discharged chamber 1253) and the buffer reservoir (discharged chamber 1254) further connecting with a pumping opening through the plurality of channels, respectively (see Fig. 12). With respect to claim 14, Hsiao teaches the diagnostic cartridge of claim 8, wherein the fluid-guide body (first channel frame 126 and second channel frame 125) further comprises a first pumping opening (cartridge side opening in communication with “the second pump 160” in [0062]) in proximity to a side of the fluid-guide body (first channel frame 126 and second channel frame 125) (see Fig. 12), and wherein the buffer reservoir (discharged chamber 1254) is located in a region between the first pumping opening (cartridge side opening in communication with “the second pump 160”) and the biosensor device (biosensor package 123) (see Fig. 12). With respect to claim 15, Hsiao teaches the diagnostic cartridge of claim 8, wherein the fluid-guide body (first channel frame 126 and second channel frame 125) further comprises a second pumping opening (cartridge side opening in communication with “the first pump 150” in [0062]) in proximity to a side of the fluid-guide body (first channel frame 126 and second channel frame 125), and wherein the sample reservoir (discharged chamber 1253) is located in a region between the second pumping opening (cartridge side opening in communication with “the first pump 150”) and the biosensor device (biosensor package 123) (see Fig. 12). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 9 is rejected under 35 U.S.C. 103 as being unpatentable over Hsiao (US20240036037) in view of Cook (US20150132860). With respect to claim 9, Hsiao teaches the diagnostic cartridge of claim 8. Hsiao fails to teach a first opening with a first cover set over the sample reservoir. In the analogous art of diagnostic cartridge, Cook teaches a first opening (upper opening of RSH reservoir 448 formed in body 422, see Fig. 18) with a first cover (top seal 340 in [0199]) set over a liquid reservoir (RSH reservoir 448 in [0201]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the diagnostic cartridge disclosed by Hsiao by providing the covered opening of Cook over Hsiao’s reservoir such that the case body comprises a first opening with a first cover set over the sample reservoir with a reasonable expectation of success for the benefit of retaining and protecting the contents of the sample reservoir (see Fig. 18 of Cook). Claim 10 is rejected under 35 U.S.C. 103 as being unpatentable over Hsiao (US20240036037) in view of Hofstadler (US20150098301). With respect to claim 10, Hsiao teaches the diagnostic cartridge of claim 8, Hsiao fails to teach a second opening with a second cover set over the buffer reservoir configured to inject a buffer liquid. In the analogous art of fluidic cartridges, Hofstadler teaches an opening (see Fig. 2C) with a cover (septum 210 in [0100]) set over a buffer reservoir (cavity 208 in [0100]) configured to inject a buffer liquid (see [0021], which recites “lading the fluidic material and/or the particle into the cavity of the cartridge. …, the fluidic material generally includes water, a buffer”). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the diagnostic cartridge disclosed by Hsiao by providing the covered opening of Hofstadler over Hsiao’s reservoir such that the case body comprises a second opening with a second cover set over the buffer reservoir configured to inject a buffer liquid with a reasonable expectation of success for the benefit of retaining and protecting the contents of the buffer reservoir (see Fig. 2C of Hofstadler) (see also [0098] of Hafstadler, which recites “a closure (e.g., a re-sealable label, a septum, or the like) is disposed in or over the aperture, e.g., to reduce the possibility of contaminating the contents of the cavity, to prevent spillage during transport, to minimize evaporation of fluidic materials in the cavity”). Claim 11 is rejected under 35 U.S.C. 103 as being unpatentable over Hsiao (US20240036037) in view of Ramsey (US20030150733). With respect to claim 11, Hsiao teaches the diagnostic cartridge of claim 8. Hsiao fails to teach two waste reservoirs adjacent to a sample reservoir and a buffer reservoir, respectively. In the analogous art of fluidic cartridges, Ramsey teaches two waste reservoirs (waste reservoirs 18F, 20F in [0172]) adjacent to the sample reservoir (first reservoirs 12F in [0172], which recites “the analyte from the first reservoir 12F’) and the buffer reservoir (buffer reservoir 16F in [0173]), respectively (see Fig. 25). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the diagnostic cartridge disclosed by Hsiao by incorporating the two waste reservoirs disclosed by Ramsey such that the fluid-guide body comprises two reservoirs adjacent to the sample reservoirs and the buffer reservoirs respectively with a reasonable expectation of success for the benefit of providing additional capacity for collecting liquids. Claim 12 is rejected under 35 U.S.C. 103 as being unpatentable over Hsiao (US20240036037) in view of Ramsey (US20030150733) in view of Jiang (WO2023173640). With respect to claim 12, Hsiao in view of Ramsey teaches the diagnostic cartridge of claim 11. Hsiao in view of Ramsey fails to teach a sealing membrane over the fluid-guide body, configured to seal the plurality of channels, the buffer reservoir, the sample reservoir, and the two waste reservoirs. In the analogous art of analytical cartridges, Jiang teaches a sealing membrane (quantitative sealing film on page 4) over a body (quantitative liquid dispensing module on page 4), configured to seal a plurality of pipes, a buffer chamber, a sample chamber, and two waste chambers (see page 4, which recites “quantitative sealing film can be detachably covered on the quantitative liquid dispensing module and used to seal each chamber of the quantitative liquid dispensing module. The quantitative sealing film seals the sample chamber, buffer chamber, quantitative chamber, residual liquid collection chamber, waste liquid collection chamber and the connecting pipes of the above chambers to ensure that sample leakage or contamination is avoided during operation”) (see also page 6, which recites “the waste liquid collection chamber includes a first waste liquid chamber 117 and a second waste liquid chamber 118”). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the diagnostic cartridge disclosed by Hsiao in view of Ramsey by incorporating the sealing membrane disclosed by Jiang such that a sealing membrane is disposed over the fluid-guide body, and is configured to seal the plurality of channels, the buffer reservoir, the sample reservoir, and the two waste reservoirs, with a reasonable expectation of success for the benefit of effectively avoiding sample leakage or contamination during operation (see page 4 of Jiang, which recites “the quantitative sealing film seals the sample chamber, buffer chamber, quantitative chamber, residual liquid collection chamber, waste liquid collection chamber and the connecting pipes of the above chambers to ensure that sample leakage or contamination is avoided during operation”). Claim 13 is rejected under 35 U.S.C. 103 as being unpatentable over Hsiao (US20240036037) in view of Huang (US20210263022). With respect to claim 13, Hsiao teaches the diagnostic cartridge of claim 8, further comprising a substrate (substrate 1232 in [0042]) electrically coupled with the biosensor device (biosensor package 123) (see [0042], which recites “the substrate 1232 includes an edge connector 1233 configured to be coupled to a circuit board, e.g., the circuit board 1010 shown in FIG. 2, such that the biosensor chip 1231 is electrically connected to the processor on the circuit board 1010 through the edge connector 1233”). Hsiao fails to teach a substrate comprising a plurality of metal pads at a lower surface of the substrate. In the analogous art of fluidic devices, Huang teaches a substrate (carrier layer 802 in [0087]) electrically coupled with a biosensor device (chip 702 in [0095]), wherein the substrate (carrier layer 802) comprises a plurality of metal pads (metal pads in [0091]) at a lower surface (bottom surface 805 in [0091]) of the substrate (carrier layer in [0091], which recites “metal pads on bottom surface 805 of carrier layer 802”) (see [0087]-[0090]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the diagnostic cartridge disclosed by Hsiao by incorporating a substrate (carrier layer 802) electrically coupled with a biosensor device (chip 702) wherein the substrate (carrier layer 802) comprises a plurality of metal pads (metal pads) at a lower surface (bottom surface 805) of the substrate (carrier layer) as disclosed by Huang such that a substrate electrically coupled with the biosensor device, wherein the substrate comprises a plurality of metal pads at a lower surface of the substrate with a reasonable expectation of success for the benefit of facilitating handling and electrical contact to a printed circuit board (see [0091] of Huang). Claim 16 is rejected under 35 U.S.C. 103 as being unpatentable over Hsiao (US20240036037) in view of Elibol (US20120061239). With respect to claim 16, Hsiao teaches the diagnostic cartridge of claim 8. Hsiao fails to teach that the biosensor device is packaged in an embedding module, and wherein the embedding module is detachable from the case body. In the analogous art of analytical devices, Elibol teaches a biosensor device (sensing chip 210 in [0027]) is packaged in an embedding module (chip assembly 250 in [0027]) and wherein the embedding module (chip assembly 250) is detachable from a device (see [0029], which recites “the holder comprising the chip to be slid out of the device and a new or different chip to be placed in the device”). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the diagnostic cartridge disclosed by Hsiao by incorporating the embedding module disclosed by Elibol such that the biosensor device is packaged in an embedding module, and wherein the embedding module is detachable from the case body with a reasonable expectation of success for the benefit of facilitating replacement of the biosensor device (see [0029] of Elibol). Claim 17 is rejected under 35 U.S.C. 103 as being unpatentable over Hsiao (US20240036037) in view of Priest (US20220362766). With respect to claim 17, Hsiao teaches the diagnostic cartridge of claim 8. Hsiao fails to teach that each of the plurality of channels in a path between the sample reservoir and the buffer reservoir comprises a plurality of U-turn structures. In the analogous art of fluidic devices, Priest teaches a plurality of U-turn structures (see [0024], which recites “the sample microfluidic channel, the pH indicator microfluidic channel and the mixing microfluidic channel are serpentine in form”) (see also Fig. 1). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the diagnostic cartridge disclosed by Hsiao by incorporating the plurality of U-tur n structures disclosed by Priest such that each of the plurality of channels in a path between the sample reservoir and the buffer reservoir comprises a plurality of U-turn structures, with a reasonable expectation of success for the benefit of thereby minimising backflow of the fluid sample (see [0024] of Priest, which recites “each serpentine channel provides some flow resistance at an upstream end of the device to thereby minimise backflow of the fluid sample”). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JONATHAN BORTOLI whose telephone number is (571)270-3179. The examiner can normally be reached 9 AM till 6 PM EST Monday through Thursday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lyle Alexander can be reached at (571)272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JONATHAN BORTOLI/Examiner, Art Unit 1797
Read full office action

Prosecution Timeline

May 07, 2024
Application Filed
Oct 23, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782348
SENSOR FOR CONVERSION OF CHEMICAL AND/OR BIOCHEMICAL INFORMATION FROM AN ANALYTE
3y 2m to grant Granted Nov 03, 2026
Patent 12779462
STRUCTURE COMPRISING MICROCHANNEL, PRODUCTION METHOD FOR SAID STRUCTURE, AND MICROCHANNEL DEVICE
2y 6m to grant Granted Nov 03, 2026
Patent 12761234
SYSTEM FOR TREATING BIOLOGICAL SAMPLES, COMPRISING A SYSTEM FOR CONVEYING HOLDERS FOR BIOLOGICAL SAMPLE CONTAINERS
2y 11m to grant Granted Oct 13, 2026
Patent 12758971
MICROFLUIDIC NUCLEOTIDE SYNTHESIZER
2y 11m to grant Granted Oct 13, 2026
Patent 12754138
DEVICE FOR PROVIDING TOTAL TRICHOME COUNT AND DENSITY OF CANNABIS INFLORESCENCES
3y 6m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+40.2%)
3y 0m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 255 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month